ArticleBioData mining2026
Deep learning multi-omics integration identifies new molecular subtypes of lung cancer.
Article in BioData mining, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer is a heterogeneous disease, with numerous subtypes differing in molecular profiles, risk factors, clinical outcomes, and tumor locations. Lung cancer, the third most diagnosed cancer in the United States, is driven by a complex combination of molecular alterations, which influence tumor behavior and patient outcomes. Large-scale consortia such as The Cancer Genome Atlas (TCGA) have generated comprehensive data sets encompassing genomic, transcriptomic, proteomic, and clinical data that present a unique opportunity to uncover novel subtypes through multi-omics integration. While clustering methods have been used to identify subtypes in lung cancer, many integrations and avenues remain underexplored. Previous studies mostly focused on a single data type for this task, potentially limiting biological insight. To address this issue, we propose a novel analytical pipeline that combines gene expression and somatic mutation data in lung cancer to identify distinct molecular subtypes. We also use an autoencoder deep neural network, as well as model-based clustering for feature extraction and clustering purposes. Integrating gene expression data, representing dynamic tumor processes with somatic mutation data, reflecting invariant genomic characteristics, enables a more comprehensive understanding of the molecular profile. We identify molecularly defined subtypes, enhancing our understanding of lung cancer's molecular heterogeneity. All source code, figures, latent features, cluster labels, and instructions for data download from the GDC are available at https://github.com/MLBC-lab/LungClust . We believe this serves as a reliable tool that offers valuable biological and clinical insights to advance precision oncology approaches in lung cancer, specifically biomarker discovery, which will aid in patient stratification and treatment response prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.